Clinical Trial Update: A Four Part Study to Investigate Relative Bioavailability, Safety and Tolerability of up to 5 Oral Formulation of GSK2251052 in Order to Identify a Formulation for Further Evaluation in a Future Later Phase Study [Phase 1]

View source ↗

Summary

Phase 1 study evaluating relative bioavailability, safety, and tolerability of up to five oral formulations of GSK2251052; the study was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Community-acquired Infection

Drugs mentioned

• GSK2251052 (GSK2251052)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Community-acquired Infection | Phase 1 | Status: TERMINATED